HT-001 is being developed to alleviate the
adverse dermatological effects experienced by cancer patients
undergoing epidermal growth factor receptor (EGFR) inhibitor
treatments. With positive progress in ongoing clinical studies,
Hoth Therapeutics aims to provide patients access to HT-001 outside
of traditional clinical trials through the Expanded Access Program
(EAP), commonly known as "compassionate use."
NEW YORK,
March 10,
2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:
HOTH), a clinical-stage biopharmaceutical company dedicated to
developing innovative therapies, today announced its intention to
submit an Expanded Access application for HT-001, its novel
therapeutic candidate for the treatment of dermatological
conditions associated with cancer therapy.
HT-001 is being developed to alleviate the
adverse dermatological effects experienced by cancer patients
undergoing epidermal growth factor receptor (EGFR) inhibitor
treatments. With positive progress in ongoing clinical studies,
Hoth Therapeutics aims to provide patients access to HT-001 outside
of traditional clinical trials through the Expanded Access Program
(EAP), commonly known as "compassionate use."
"Submitting an Expanded Access application is an
important step in our commitment to ensuring patients who may
benefit from HT-001 have the opportunity to receive this promising
treatment," said Robb Knie, CEO of
Hoth Therapeutics. "We remain dedicated to advancing solutions that
address critical unmet medical needs and improve quality of life
for patients undergoing cancer treatment."
The Expanded Access Program is designed to
provide investigational treatments to patients with serious or
life-threatening conditions who lack comparable treatment options.
Through this program, Hoth Therapeutics seeks to offer HT-001 to
eligible patients while continuing to gather valuable data on its
safety and efficacy.
For more information about HT-001, ongoing
clinical trials, or the Expanded Access Program, please
visit www.hoththerapeutics.com
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage
biopharmaceutical company dedicated to developing innovative,
impactful, and ground-breaking treatments with a goal to improve
patient quality of life. We are a catalyst in early-stage
pharmaceutical research and development, elevating drugs from the
bench to pre-clinical and clinical testing. Utilizing a
patient-centric approach, we collaborate and partner with a team of
scientists, clinicians, and key opinion leaders to seek out and
investigate therapeutics that hold immense potential to create
breakthroughs and diversify treatment options. To learn more,
please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release
includes forward-looking statements based upon Hoth's
current expectations, which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth
may not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors"
in Hoth's most recent Annual Report on Form 10-K and Hoth's
other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors
LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-plans-to-submit-expanded-access-application-for-ht-001-to-support-cancer-patients-in-need-302396474.html
SOURCE Hoth Therapeutics, Inc.
